康芝药业: 关于购买董监高责任险的公告

Core Viewpoint - The company plans to purchase liability insurance for its directors, supervisors, and senior management to enhance its risk management system and protect the interests of the company and its investors [1][2]. Group 1: Insurance Plan - The insurance contract will be negotiated based on market prices, with a premium not exceeding 300,000 yuan per year for renewal or reinsurance [2]. - The company aims to ensure that the insurance covers all directors, supervisors, and senior management, thereby promoting effective decision-making and management within their respective responsibilities [1][2]. Group 2: Authorization Matters - The board of directors has proposed to authorize the management to handle all matters related to the purchase of the liability insurance, including determining the scope of insured individuals, selecting the insurance company, and signing relevant legal documents [1][2]. Group 3: Review Procedure - The proposal for purchasing the liability insurance was reviewed by the board and supervisory committee, with all relevant parties abstaining from voting due to their status as insured individuals [2]. - The supervisory committee supports the purchase, stating it will improve the company's risk management and create a favorable governance environment for sustainable development [2].